Home Uncategorized Page 10

Uncategorized

Latest

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

Markets for Feb 24: $AION -18.75%, $TRIP +12.64%, $MCUR +11.53%

A New Path To Wealth: Navigating The Psychedelic Investment Landscape

February’s Psychedelic Capital Investigates Institutional Vs Retail Investor Impact

Psychedelic Guides with Ketan Patel of Next Healthcare Technologies Inc

Markets for Feb 20: $COOL +15.89%, $EHVVF -12.36%, $SILO +11.11%

Psychedelic Spotlight: The Conscious Fund

PsyCap Recap: 3 Key Takeaways From the Shroom Bloom Psychedelic Capital...

Markets for Feb 17: EHVVF +17.85%, MSET +15.04%, NM +8.93%

Psychedelic Guides with Joya Halls

PsyCap Recap: 3 Key Takeaways From the January 2021 Mindset Pharma...

1...91011...13 Page 10 of 13

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.